0.1800USD0.00%Mkt Cap: 1.62M USDP/E: —Last update: 2026-05-22
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholest…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.62M USD
Enterprise Value2.35M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-24.95M USD
Revenue/Share—
Last Price0.1800 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.04
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.12
EPS (TTM)-3.67
EPS (Forward)-4.80
52W Range
0.11004% of range1.670
52W High1.670 USD
52W Low0.1100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE201.44%
ROA-7172.26%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.11M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-128.44%
Net Debt897.34K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.05
Quick Ratio0.02
Book Value/Sh-1.4480 USD
Cash/Share0.0370 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 26, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.8.10M
Float7.68M
Insiders0.02%
Institutions5.15%
Short Interest
Short Ratio0.3d
Short % Float7.38%
Short % Out.7.37%
Shares Short359.25K
Short (prev mo.)300.95K
Technical
SMA 500.2063 (-12.8%)
SMA 2000.1755 (+2.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)10.04K
Avg Vol (10d)9.35K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—